STING1 and Familial prostate cancer: We next evaluated the combination of YJ1206 and anti–PD-1 across various syngeneic models, including Myc-CaP (prostate cancer), B16-F10 (melanoma), CT26 (colon cancer), and LLC (lung cancer), after confirming that activation of STING by intratumoral administration of cGAMP led to strong suppression of tumor growth and enhanced ICB efficacy (Figure 4C).